Efficacy of phase 3 trial of RTS, S/AS01 malaria vaccine: The need for an alternative development plan

References

• Schwartz L, Brown GV, Genton B, Moorthy VS. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malaria J 2012; 11(1):1; PMID:22212246; http://dx.doi.org/10.1186/1475-2875-11-11
   PubMed Web of Science ®Google Scholar
• Hoffman SL, Vekemans J, Richie TL, Duffy PE. The march toward malaria vaccines. Am J Preventive Med 2015; 49(6):S319-S33; PMID:26590432; http://dx.doi.org/10.1016/j.amepre.2015.09.011
   PubMed Web of Science ®Google Scholar
• Moorthy V, Reed Z, Smith PG, WHO Study Group on Measures of Malaria Vaccine Efficacy. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Vaccine 2007; 25(28):5115-23; PMID:17577487; http://dx.doi.org/10.1016/j.vaccine.2007.01.085
   PubMedGoogle Scholar
• Birkett AJ. Status of vaccine research and development of vaccines for malaria. Vaccine 2016; 34(26):2915-20; PMID:26993333; http://dx.doi.org/10.1016/j.vaccine.2015.12.074
   PubMed Web of Science ®Google Scholar
• Ballou WR, Arevalo-Herrera M, Carucci D, Richie TL, Corradin G, Diggs C, Druilhe P, Giersing BK, Saul A, Heppner DG, et al. Update on the clinical development of candidate malaria vaccines. Am J Tropical Med Hygiene 2004; 71(2 suppl):239-47; PMID:15331843
   PubMed Web of Science ®Google Scholar
• Moorthy VS, Good MF, Hill AV. Malaria vaccine developments. Lancet 2004; 363(9403):150-6; http://dx.doi.org/10.1016/S0140-6736(03)15267-1
   PubMed Web of Science ®Google Scholar
• Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garçon N, Krzych U, Marchand M. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Eng J Med 1997; 336(2):86-91; PMID:8988885; http://dx.doi.org/10.1056/NEJM199701093360202
   PubMed Web of Science ®Google Scholar
• Stoute J, Kester K, Krzych U, Wellde B, Hall T, White K, Glenn G, Ockenhouse CF, Garcon N, Schwenk R, et al. Long-term efficacy and immune responses following immunization with the RTS, S malaria vaccine. J Infect Dis 1998; 178(4):1139-44; PMID:9806046; http://dx.doi.org/10.1086/515657
   PubMed Web of Science ®Google Scholar
• Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, Krzych U, Delchambre M, Voss G, Dowler MG, et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 2001; 183(4):640-7; PMID:11170991; http://dx.doi.org/10.1086/318534
   PubMed Web of Science ®Google Scholar
• Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, et al. Efficacy of RTS, S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001; 358(9297):1927-34; http://dx.doi.org/10.1016/S0140-6736(01)06957-4
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, et al. Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004; 364(9443):1411-20; http://dx.doi.org/10.1016/S0140-6736(04)17223-1
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, Sigauque B, Milman J, Mandomando I, Bassat Q, et al. Duration of protection with RTS, S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005; 366(9502):2012-8; http://dx.doi.org/10.1016/S0140-6736(05)67669-6
   PubMed Web of Science ®Google Scholar
• Garçon N, Heppner DG, Cohen J. Development of RTS, S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines 2003; 2(2):231-8; PMID:12899574; http://dx.doi.org/10.1586/14760584.2.2.231
   PubMedGoogle Scholar
• Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009; 30(1):23-32; PMID:19059004; http://dx.doi.org/10.1016/j.it.2008.09.006
   PubMed Web of Science ®Google Scholar
• Coppi A, Natarajan R, Pradel G, Bennett BL, James ER, Roggero MA, Corradin G, Persson C, Tewari R, Sinnis P. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J Exp Med 2011; 208(2):341-56; PMID:21262960; http://dx.doi.org/10.1084/jem.20101488
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 2014; 11(7):e1001685; PMID:25072396; http://dx.doi.org/10.1371/journal.pmed.1001685
   PubMed Web of Science ®Google Scholar
• Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S, Lang T, Gould J, Dubois MC, et al. Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age. N Eng J Med 2008; 359(24):2521-32; PMID:19064627; http://dx.doi.org/10.1056/NEJMoa0807381
   PubMed Web of Science ®Google Scholar
• Asante KP, Abdulla S, Agnandji S, Lyimo J, Vekemans J, Soulanoudjingar S, Owusu R, Shomari M, Leach A, Jongert E, et al. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis 2011; 11(10):741-9; PMID:21782519; http://dx.doi.org/10.1016/S1473-3099(11)70100-1
   PubMed Web of Science ®Google Scholar
• Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Jr, Hall T, Wellde BT, White K, Sun P, Schwenk R, et al. A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults. Vaccine 2007; 25(29):5359-66; PMID:17574311; http://dx.doi.org/10.1016/j.vaccine.2007.05.005
   PubMed Web of Science ®Google Scholar
• Gosling R, von Seidlein L. The Future of the RTS, S/AS01 Malaria Vaccine: An alternative development plan. PLoS Med 2016; 13(4):e1001994; PMID:27070151; http://dx.doi.org/10.1371/journal.pmed.1001994
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet (London, England) 2015; 386(9988):31-45; PMID:25913272; http://dx.doi.org/10.1016/S0140-6736(15)60721-8
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmüller B, Issifou S, Kremsner PG, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367(24):2284-95; PMID:23136909; http://dx.doi.org/10.1056/NEJMoa1208394
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmüller B, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365(20):1863-75; PMID:22007715; http://dx.doi.org/10.1056/NEJMoa1102287
   PubMed Web of Science ®Google Scholar
• Daily JP. Malaria vaccine trials—beyond efficacy end points. N Eng J Med 2012; 367(24):2349-51; PMID:23136910; http://dx.doi.org/10.1056/NEJMe1213392
   PubMed Web of Science ®Google Scholar
• Girard MP, Reed ZH, Friede M, Kieny MP. A review of human vaccine research and development: malaria. Vaccine 2007; 25(9):1567-80; PMID:17045367; http://dx.doi.org/10.1016/j.vaccine.2006.09.074
   PubMed Web of Science ®Google Scholar
• Lorenz V, Karanis G, Karanis P. Malaria vaccine development and how external forces shape it: an overview. Int J Environmental Res Public Health 2014; 11(7):6791-807; PMID:24983392; http://dx.doi.org/10.3390/ijerph110706791
   PubMed Web of Science ®Google Scholar
• Good MF. Towards a blood-stage vaccine for malaria: are we following all the leads? Nat Rev Immunol 2001; 1(2):117-25; PMID:11905819; http://dx.doi.org/10.1038/35100540
   PubMed Web of Science ®Google Scholar
• Muller O, Tozan Y, Becher H. RTS,S/AS01 malaria vaccine and child mortality. Lancet (London, England) 2015; 386(10005):1736; PMID:26545434; http://dx.doi.org/10.1016/S0140-6736(15)00694-7
   PubMed Web of Science ®Google Scholar
• Klein SL, Shann F, Moss WJ, Benn CS, Aaby P. RTS,S Malaria vaccine and increased mortality in girls. MBio 2016; 7(2):e00514-16; PMID:27118593; http://dx.doi.org/10.1128/mBio.00514-16
   PubMed Web of Science ®Google Scholar
• Lee SM, Wu CK, Plieskatt J, McAdams DH, Miura K, Ockenhouse C, King CR. Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates. Malar J 2016; 15(1):405; PMID:27515826; http://dx.doi.org/10.1186/s12936-016-1464-6
   PubMed Web of Science ®Google Scholar
• Birkett AJ, Moorthy VS, Loucq C, Chitnis CE, Kaslow DC. Malaria vaccine R&D in the decade of vaccines: breakthroughs, challenges and opportunities. Vaccine 2013; 31:B233-B43PMID:23598488; http://dx.doi.org/10.1016/j.vaccine.2013.02.040
   PubMed Web of Science ®Google Scholar